Moderna's $2B offering; AstraZeneca-Amgen and Biokin chalk up Phase 3 wins

Plus news about Takeda China and ProFound. Moderna's $2B offering: The mRNA biotech will offer convertible senior notes for the "flexibility to invest" in growing its oncology business and repay debt ...